The European Medicines Agency (EMA) has granted marketing authorization to the first ustekinumab biosimilar, STADA Arzneimittel and Alvotech’s Uzpruvo.
The European Medicines Agency (EMA) granted marketing authorization to Uzpurvo, the first biosimilar to reference Stelara (ustekinumab). The biosimilar is indicated for Crohn disease, psoriatic arthritis, and plaque psoriasis.
The product was developed by Alvotech and will be marketed by STADA Arzneimittel as part of a 2019 exclusive commercialization agreement. Uzpruvo is expected to be available to patients following the July 2024 expiry of a European Supplementary Protection Certificate for Stelara.
“This first marketing authorization for biosimilar ustekinumab in Europe offers the potential to expand substantially patient access through competition. By adding to our current roster of 6 marketed biosimilars, STADA looks forward to offering Europe’s gastroenterologists, dermatologists, and rheumatologists a further cost-effective treatment option,” commented Bryan Kim, global specialty head at STADA, in a company statement.
According to STADA, the European market for ustekinumab is worth about €2.5 billion (US$2.7 billion) and the introduction of Uzpurvo and products like it will greatly expand patient access to ustekinumab treatment for millions of patients with gastrointestinal, dermatologic, and rheumatic conditions.
“With around 95,000 patients already using ustekinumab in the top-4 EU markets plus the UK, Stelara ranks among Europe’s top-10 medicine brands…. Biosimilar competition upon expiry of EU exclusivity rights for Stelara offers a significant opportunity to improve patient access at the same, or even lower, costs to European health care systems,” wrote the company.
The authorization came after the EMA’s Committee for Medicinal Products for Human Use took on a positive opinion on approving Uzpurvo in November 2023. The partners announced that the EMA accepted their marketing authorization application for Uzpurvo, at the time called AVT04. The applications included analytical and clinical data, including data from the AVT04-GL-301 confirmatory clinical, safety, and efficacy study demonstrating therapeutic equivalence between AVT04 and Stelara in patients with moderate to severe chronic plaque-type psoriasis. Similarity between the products’ pharmacokinetic profiles was evaluated in the AVT04-GL-101 study.
Uzpruvo, a human IgG1κ monoclonal antibody, is generated in Sp2/0 cells through the perfusion process, mirroring the manufacturing approach of the reference product. Specifically designed, Uzpruvo selectively focuses on the p40 protein, present in both interleukin (IL)-12 and IL-23 cytokines, pivotal in addressing immune-mediated conditions such as Crohn disease, psoriasis, and psoriatic arthritis.
Anil Okay, chief commerical officer of Alvotech, remarked, “We look forward to spearheading biosimilars competition in the ustekinumab market and increasing patient access to biologic therapies for inflammatory conditions as we have done with our adalimumab biosimilar, launched last year.”
Overcoming Challenges to Improve Access and Reduce Costs
November 12th 2024Biosimilars hold the potential to dramatically lower health care costs and improve access to life-changing treatments, but realizing this potential will require urgent policy reforms, market competition, and better education for both providers and patients.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Challenges, Obstacles, and Future Directions for Anti-TNF Biosimilars in IBD
November 9th 2024A review article on tumor necrosis factor (TNF)-α inhibitors in inflammatory bowel disease (IBD) outlined current use of anti-TNF originators and biosimilars, their efficacy and safety, the benefits and challenges of biosimilars, and the future of biosimilars in IBD.
Eye on Pharma: Henlius, Organon Updates; Meitheal Portfolio Expansion; Celltrion Zymfentra Data
November 5th 2024Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous infliximab (Zymfentra) showed monotherapy could be as effective as combination therapy for inflammatory bowel disease.